Sutro Biopharma, Inc.

56 articles with Sutro Biopharma, Inc.

• Sutro Biopharma to Present at the 18th Annual Needham Healthcare Conference

  4/4/2019

  Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9 at 4:50 p.m. ET at the Westin Grand Central Hotel in New York.

• 

  Changing the Public’s Perception of the Biopharma Industry

  4/3/2019

  Public perception of the industry can be a bit confusing. Life Science Leader recently pulled together several biopharma executives for a round table discussion of the biopharma industry’s public perception—generally bad—and what might be able to do about it.

• Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments

  4/1/2019

  STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019

• Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers

  3/15/2019

  Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that it has dosed the first patient in a Phase I study of STRO-002, an anti-folate receptor alpha (FoIRα) antibody-drug conjugate (ADC), in patients with ovarian and endometrial cancers.

• Sutro Biopharma to Present at the Cowen and Company 39th Annual Health Care Conference

  3/5/2019

  Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11 at 2:50 p.m. ET at the Marriott Copley Place in Boston.

• Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry

  1/29/2019

  - Veteran Pfizer researcher Andreas Maderna, Ph.D., joins the company

• Sutro to Present at 37th Annual J.P. Morgan Healthcare Conference

  1/3/2019

  Sutro Biopharma, Inc. today announced that Bill Newell, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 10, 2019 at 11:30 a.m. PT / 2:30 p.m. ET at the Westin St. Francis Hotel in San Francisco.

• Sutro Achieves $10 Million Milestone Payment from Celgene

  12/19/2018

  Sutro develops successful spray drying technology marking a major advancement in commercial-scale manufacturing capabilities

• Sutro to Participate in the 30th Annual Piper Jaffray Healthcare Conference

  11/26/2018

  Sutro Biopharma, Inc. will present at the 30th Annual Piper Jaffray Healthcare Conference.

• Sutro Biopharma Reports Third Quarter 2018 Financial Results

  11/14/2018

  STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma

• 

  BioSpace Movers and Shakers Nov. 12

  11/12/2018

  Biopharma companies name new members of their leadership teams. Who made big moves this week?

• Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors

  11/8/2018

  Sharp to Bring Additional Financial Expertise to Sutro's Board

• Sutro's STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

  10/12/2018

  A New Generation of Precisely Engineered CD74-Targeting ADC

• 

  On the Heels of bluebird bio Collaboration, Gritstone Secures $100 Million in IPO

  9/28/2018

  Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.

• Sutro Biopharma Announces $85.0 Million Initial Public Offering

  9/27/2018

  Sutro Biopharma, Inc. today announced the pricing of its initial public offering of 5,667,000 shares of its common stock at a price to the public of $15.00 per share.

• 

  A Look at 7 Upcoming and Recently Announced Biotech IPOs

  9/24/2018

  According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
• 

  Awash in Funding, Sutro Biopharma Files for $75 Million IPO

  8/30/2018

  Only a month after raising $85.4 million in a Series E financing, Sutro Biopharma filed for an initial public offering (IPO). The company plans to raise $75 million with the IPO.

• Sutro and The Leukemia & Lymphoma Society Partner on Lymphoma and Multiple Myeloma Treatment

  8/13/2018

  Sutro Biopharma, Inc., and The Leukemia & Lymphoma Society® , or LLS, are partnering to develop STRO-001, Sutro’s CD74-targeting antibody-drug conjugate, to treat relapsed and/or refractory multiple myeloma and non-Hodgkin’s lymphoma.

• Sutro Biopharma Announces $85.4 Million Series E Round

  7/26/2018

  Sutro Biopharma, Inc., has secured $85.4 million in Series E financing to advance its wholly-owned pipeline of novel cancer therapeutics, including two internally-developed antibody drug conjugates, or ADCs, known as STRO-001, now in Phase 1 clinical testing for lymphoma and multiple myeloma, and STRO-002, which is expected to enter clinical trials for ovarian and endometrial cancer by early 2019.

• Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders

  7/24/2018

  Sutro's Cell-free Protein Synthesis Technology is Paired With Merck's Immunology & Cancer Expertise